Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2055-0464
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy ; volume:3 ; number:3 ; day:1 ; month:9 ; year:2016 ; pages:79-84 ; date:9.2016
Echo Research and Practice ; 3, Heft 3 (1.9.2016), 79-84, 9.2016
- Urheber
-
Boczar, Kevin Emery
Aseyev, Olexiy
Sulpher, Jeffrey
Johnson, Christopher
Burwash, Ian G.
Turek, Michele
Dent, Susan
Dwivedi, Girish
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1530/ERP-16-0020
- URN
-
urn:nbn:de:101:1-2022052418595658153823
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Boczar, Kevin Emery
- Aseyev, Olexiy
- Sulpher, Jeffrey
- Johnson, Christopher
- Burwash, Ian G.
- Turek, Michele
- Dent, Susan
- Dwivedi, Girish
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anthracycline Chemotherapy and Cardiotoxicity
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Detection of right ventricular dysfunction by three – dimensional echocardiography and two - dimensional speckle tracking in breast cancer patients receiving anthracycline- based chemotherapy
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
PITX2 DNA methylation predicts response to anthracycline-based chemotherapy in triple negative breast cancer
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Anthracycline Chemotherapy and Cardiotoxicity
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Detection of right ventricular dysfunction by three – dimensional echocardiography and two - dimensional speckle tracking in breast cancer patients receiving anthracycline- based chemotherapy
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
PITX2 DNA methylation predicts response to anthracycline-based chemotherapy in triple negative breast cancer
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
Anthracycline Chemotherapy and Cardiotoxicity
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
Detection of right ventricular dysfunction by three – dimensional echocardiography and two - dimensional speckle tracking in breast cancer patients receiving anthracycline- based chemotherapy
Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
PITX2 DNA methylation predicts response to anthracycline-based chemotherapy in triple negative breast cancer
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer